| Health / Medical Topics |
Laropiprant
A prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of DP1, a G-protein coupled receptor. Via competing with prostaglandin D2 (PG D2) for binding to DP1, this agent prevents PG D2-induced vasodilation and increased blood flow. As niacin induces the synthesis of PG D2, predominantly in the skin, administration of laropiprant may prevent niacin-induced vasodilation in the skin and facial flushing. (NCI Thesaurus)
YOU MAY ALSO LIKE
A drug used to treat acute myelogenous leukemia (AML). It is also being studied in the treatment of several other types of…
A proprietary tablet formulation containing an extract from Largetrifoliolious Bugbane rhizome (Shengma), the dried root of Cimicifuga sp., with potential use for…
Greatest in size of those under consideration.
The process of determining of the precise sequence of nucleotides over a very large piece of DNA, possibly the entire genome of…
The determination of the ratio of large unstained cells compared to leukocytes present in a sample. The measurement may be expressed as…
The determination of the number of large unstained cells present in a sample.
